Published in
Taylor and Francis Group, Leukemia & Lymphoma, 12(61), p. 3014-3017, 2020
DOI: 10.1080/10428194.2020.1795161
Links
Tools
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience
Journal article published in 2020 by
Ahmed Sawas,
Helen Ma 
,
John Kuruvilla ,
Jennifer K. Lue,
Changchun Deng,
Enrica Marchi,
Francesca Montanari,
Bin Cheng,
Kerry J. Savage,
Diego Villa ,
Michael Crump,
Joseph M. Connors,
Owen A. O’Connor
,
John Kuruvilla ,
Jennifer K. Lue,
Changchun Deng,
Enrica Marchi,
Francesca Montanari,
Bin Cheng,
Kerry J. Savage,
Diego Villa ,
Michael Crump,
Joseph M. Connors,
Owen A. O’Connor
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 